<p>A hallmark of pulmonary fibrosis is the aberrant activation of lung fibroblasts into pathological fibroblasts that produce excessive extracellular matrix<sup><CitationRef AdditionalCitationIDS="CR2" CitationID="CR1">1</CitationRef>–<CitationRef CitationID="CR3">3</CitationRef></sup>. Thus, the identification of key regulators that promote the generation of pathological fibroblasts can inform the development of effective countermeasures against disease progression. Here we use two mouse models of pulmonary fibrosis to show that LEPR<sup>+</sup> fibroblasts that arise during alveologenesis include SCUBE2<sup>+</sup> alveolar fibroblasts as a major constituent. These alveolar fibroblasts in turn contribute substantially to CTHRC1<sup>+</sup>POSTN<sup>+</sup> pathological fibroblasts. Genetic ablation of POSTN<sup>+</sup> pathological fibroblasts attenuates fibrosis. Comprehensive analyses of scRNA-seq and scATAC-seq data reveal that RUNX2 is a key regulator of the expression of fibrotic genes. Consistently, conditional deletion of <i>Runx2</i> with <i>Lepr</i><sup><i>creERT2</i></sup> or <i>Scube2</i><sup><i>creERT2</i></sup> reduces the generation of pathological fibroblasts, extracellular matrix deposition and pulmonary fibrosis. Therefore, LEPR<sup>+</sup> cells that include SCUBE2<sup>+</sup> alveolar fibroblasts are a key source of pathological fibroblasts, and targeting <i>Runx2</i> provides a potential treatment option for pulmonary fibrosis.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

RUNX2 promotes fibrosis via an alveolar-to-pathological fibroblast transition

  • Yinshan Fang,
  • Sanny S. W. Chung,
  • Le Xu,
  • Chenyi Xue,
  • Xue Liu,
  • Dianhua Jiang,
  • Rongbo Li,
  • Yohei Korogi,
  • Ke Yuan,
  • Anjali Saqi,
  • Hanina Hibshoosh,
  • Yuefeng Huang,
  • Chyuan-Sheng Lin,
  • Takeshi Takarada,
  • Tatsuya Tsukui,
  • Dean Sheppard,
  • Xin Sun,
  • Jianwen Que

摘要

A hallmark of pulmonary fibrosis is the aberrant activation of lung fibroblasts into pathological fibroblasts that produce excessive extracellular matrix13. Thus, the identification of key regulators that promote the generation of pathological fibroblasts can inform the development of effective countermeasures against disease progression. Here we use two mouse models of pulmonary fibrosis to show that LEPR+ fibroblasts that arise during alveologenesis include SCUBE2+ alveolar fibroblasts as a major constituent. These alveolar fibroblasts in turn contribute substantially to CTHRC1+POSTN+ pathological fibroblasts. Genetic ablation of POSTN+ pathological fibroblasts attenuates fibrosis. Comprehensive analyses of scRNA-seq and scATAC-seq data reveal that RUNX2 is a key regulator of the expression of fibrotic genes. Consistently, conditional deletion of Runx2 with LeprcreERT2 or Scube2creERT2 reduces the generation of pathological fibroblasts, extracellular matrix deposition and pulmonary fibrosis. Therefore, LEPR+ cells that include SCUBE2+ alveolar fibroblasts are a key source of pathological fibroblasts, and targeting Runx2 provides a potential treatment option for pulmonary fibrosis.